About
Articles by Paul
-
England & Company Ranks #1 in Orthopedic Medical Device Investment Banking
England & Company Ranks #1 in Orthopedic Medical Device Investment Banking
By Paul Teitelbaum
-
The England & Company Healthcare Investment Banking Team Does it Again! Third Orthopedic Transaction of 2019.
The England & Company Healthcare Investment Banking Team Does it Again! Third Orthopedic Transaction of 2019.
By Paul Teitelbaum
-
The England & Company Healthcare Investment Banking Team Closes First Institutional Financing for Catalyst OrthoScience
The England & Company Healthcare Investment Banking Team Closes First Institutional Financing for Catalyst OrthoScience
By Paul Teitelbaum
Activity
-
We’re thrilled about our recent #MedicalEducation event hosted by Steven Goldberg, MD from Orthopedic Surgery & Sports Medicine in Naples, FL…
We’re thrilled about our recent #MedicalEducation event hosted by Steven Goldberg, MD from Orthopedic Surgery & Sports Medicine in Naples, FL…
Liked by Paul Teitelbaum
-
Make Joint Prep Simple with The Cartilaginator®! A revolutionary joint preparation technology designed to precisely the indicated joint in a fast and…
Make Joint Prep Simple with The Cartilaginator®! A revolutionary joint preparation technology designed to precisely the indicated joint in a fast and…
Liked by Paul Teitelbaum
-
We are thrilled to announce the launch of our brand-new website, www.TheCartilaginator.com Discover how The Cartilaginator is revolutionizing joint…
We are thrilled to announce the launch of our brand-new website, www.TheCartilaginator.com Discover how The Cartilaginator is revolutionizing joint…
Liked by Paul Teitelbaum
Experience & Education
Publications
-
Medical Device Market Update (MedDevNews) - Q3 2018
England & Company
Overview of M&A and financing activity and trends in the medical device market, from both OEM and outsourcing perspectives.
Other authorsSee publication -
Deal Making in Orthopedics
Today's Medical Developments
In the wake of Zimmer's $13.4 billion acquisition of Biomet, which was announced April 2014, Paul Teitelbaum discusses the drivers behind the wave of M&A activity in the orthopedic medical device sector that began in 2012, heated up in late 2013 / early 2014 and is expected to continue in 2015. See pages 66-69. In addition to its normal circulation, the publication is being distributed at the International Manufacturing Technology Show (IMTS) 2014 in Chicago, September 8-13.
-
Assessment of Military Specifications Employing Ozone-Depleting Chlorofluorocarbons and Halons
ICF International
Under DoD Security Clearance, inspected and investigated thousands of military specifications ("mil specs") related to a wide range of military assets and activities, ranging from weapons systems to uniforms to fire extinguishers to service and maintenance of assets. Identified 262 military assets or activities employing the use of CFCs or halons for further analysis and replacement with alternative substances. Report was delivered to the Office of the Secretary of Defence (OSD) in early…
Under DoD Security Clearance, inspected and investigated thousands of military specifications ("mil specs") related to a wide range of military assets and activities, ranging from weapons systems to uniforms to fire extinguishers to service and maintenance of assets. Identified 262 military assets or activities employing the use of CFCs or halons for further analysis and replacement with alternative substances. Report was delivered to the Office of the Secretary of Defence (OSD) in early 1990, under Richard B. Cheney, as a response to DoD Directive AD 272-651 of Feb. 13, 1989 issued by William H. Taft, former Deputy Secretary of Defense. Report was also cited at worldwide meetings related to enforcement of the 1987 Montreal Protocol and in various media.
-
Toxicological Profiles on Contaminants found at Hazardous Waste Sites
Agency for Toxic Substances and Disease Registry (ATSDR)
Contributing author on Toxicological Profiles published by the Agency for Toxic Substances and Disease Registry (ATSDR) on several toxic substances found at Superfund (1980 CERCLA) hazardous waste sites. Chemical Profiles included mercury, lead, selenium, 1,2-dichloroethane, 1,1,2-trichloroethane, trichloroethylene, toxaphene, bromodichloromethane and others. As an employee at a consulting firm which was a sub-contractor to ATSDR, contributed to the sections of these Profiles related to health…
Contributing author on Toxicological Profiles published by the Agency for Toxic Substances and Disease Registry (ATSDR) on several toxic substances found at Superfund (1980 CERCLA) hazardous waste sites. Chemical Profiles included mercury, lead, selenium, 1,2-dichloroethane, 1,1,2-trichloroethane, trichloroethylene, toxaphene, bromodichloromethane and others. As an employee at a consulting firm which was a sub-contractor to ATSDR, contributed to the sections of these Profiles related to health effects; chemical and physical properties; production, import/export, use and disposal; and references/bibliography.
Other authors -
Projects
-
$18 million Convertible Debt Financing for Extremity Medical, LLC
-
-
Strategic Partnership Between Extremity Medical and Henry Schein
-
-
$55 Million Growth Financing for Specialty Pharmacy Company OneroRx
-
-
Debt Financing for Extremity Medical, LLC
-
-
Sale of SEAL Foot & Ankle External Fixation business to Enovis (Nasdaq: ENOV)
-
-
Buy-Side in Orthopedic Contract Manufacturing for Asian Conglomerate
-
-
$38 million Capital Raise for OSSIO, led by MVM
-
-
Sale of Additive Orthopaedics to Paragon 28 (NYSE: FNA)
-
-
Sale of Trilliant Surgical to DJO, subsidiary of Colfax (NYSE: CFX)
-
-
Sale of Collagen Solutions to Rosen's Diversified (RDI)
-
-
Sale of BioMedical Enterprises, Inc. (BME) to the DePuy Synthes Companies of Johnson & Johnson
-
-
Sale of Flexan to Linden Capital Partners
-
-
Representation of Unsecured Creditors in Sale of Savient Pharmaceuticals to GTCR-backed Crealta
-
-
Strategic advisor to Ekso Bionics in its public offering
-
-
Sale of Novologix, Inc. to CVS/Caremark
-
-
$25 million Financing for a an innovative joint replacement and sports medicine company
-
-
Financing for a disruptive spinal implant company
-
-
Growth equity financings for a trauma and extremities orthopedic company
-
-
Growth financing for a disruptive air purification technology company
-
-
Sale of a disruptive extremities and sports medicine motion preservation platform technology company
-
Languages
-
French
Limited working proficiency
-
Hebrew
Elementary proficiency
-
Spanish
Elementary proficiency
Recommendations received
6 people have recommended Paul
Join now to viewMore activity by Paul
-
We'll be exhibiting at OMTEC 2024 in Chicago. As a leading provider of contract manufacturing solutions for the orthopedic device industry, we invite…
We'll be exhibiting at OMTEC 2024 in Chicago. As a leading provider of contract manufacturing solutions for the orthopedic device industry, we invite…
Liked by Paul Teitelbaum
-
From panels to parties and parades, the University welcomed alumni back to campus to reminisce about their time at Penn. Ned Weiser, a 1982 graduate…
From panels to parties and parades, the University welcomed alumni back to campus to reminisce about their time at Penn. Ned Weiser, a 1982 graduate…
Liked by Paul Teitelbaum
-
The BioPoly team had a great time at the American Shoulder and Elbow Surgeons (ASES) Foundation Meeting last evening! The excitement around our…
The BioPoly team had a great time at the American Shoulder and Elbow Surgeons (ASES) Foundation Meeting last evening! The excitement around our…
Liked by Paul Teitelbaum
-
OneroRx is proud to once again be Certified™ by Great Place To Work®. This award is based entirely on what current employees say about their…
OneroRx is proud to once again be Certified™ by Great Place To Work®. This award is based entirely on what current employees say about their…
Liked by Paul Teitelbaum
-
So, who among my connections knows Edelson PC and how can I get them to do this with University of Pennsylvania, my alma mater, where my daughter is…
So, who among my connections knows Edelson PC and how can I get them to do this with University of Pennsylvania, my alma mater, where my daughter is…
Liked by Paul Teitelbaum
-
Our portfolio company ZygoFix Ltd. received FDA regulatory clearance for its zLOCK Lumbar Facet Fixation System. ZygoFix is addressing the unmet…
Our portfolio company ZygoFix Ltd. received FDA regulatory clearance for its zLOCK Lumbar Facet Fixation System. ZygoFix is addressing the unmet…
Liked by Paul Teitelbaum
-
Our Orthodontics team had an incredible showing at AAO 2024! The launch of our Smilers Aligners, INFINiTi Loops and Motion Pro Clear products…
Our Orthodontics team had an incredible showing at AAO 2024! The launch of our Smilers Aligners, INFINiTi Loops and Motion Pro Clear products…
Liked by Paul Teitelbaum
-
Highridge Medical is excited to announce that Glen A. Kashuba has been named Chief Executive Officer of EBI. In addition to continuing as a board…
Highridge Medical is excited to announce that Glen A. Kashuba has been named Chief Executive Officer of EBI. In addition to continuing as a board…
Liked by Paul Teitelbaum
-
The countdown begins! Only a few more days until the start of the American Shoulder and Elbow Surgeons Foundation 2024 National Shoulder & Elbow Week…
The countdown begins! Only a few more days until the start of the American Shoulder and Elbow Surgeons Foundation 2024 National Shoulder & Elbow Week…
Liked by Paul Teitelbaum
-
We are honored to share our story in the most recent issue of Chain Drug Review! View the article on our website: https://lnkd.in/e_TxZkA4 or the…
We are honored to share our story in the most recent issue of Chain Drug Review! View the article on our website: https://lnkd.in/e_TxZkA4 or the…
Liked by Paul Teitelbaum
-
ZygoFix Ltd. (#LSIAlumni) received FDA clearance for its zLOCK Lumbar Facet Fixation System. Traditional spinal fusion methods require placement of…
ZygoFix Ltd. (#LSIAlumni) received FDA clearance for its zLOCK Lumbar Facet Fixation System. Traditional spinal fusion methods require placement of…
Liked by Paul Teitelbaum
-
How do you manage a 72-year-old active patient who received a humeral nail for a gunshot wound over 20 years ago and now needs their shoulder…
How do you manage a 72-year-old active patient who received a humeral nail for a gunshot wound over 20 years ago and now needs their shoulder…
Liked by Paul Teitelbaum
-
Catalyst is proud to sponsor the Welcome Reception at SHOULDER360 on May 1st. Don’t miss this chance to kick off Shoulder360 in style and to learn…
Catalyst is proud to sponsor the Welcome Reception at SHOULDER360 on May 1st. Don’t miss this chance to kick off Shoulder360 in style and to learn…
Liked by Paul Teitelbaum
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Paul Teitelbaum
-
Paul Teitelbaum
-
Paul Teitelbaum
Application Developer at University of Arizona Foundation
-
Paul Teitelbaum
Laborer at International Action Center
3 others named Paul Teitelbaum are on LinkedIn
See others named Paul Teitelbaum